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Abstract
Many targeted cancer therapies require endocytosis of the targeting molecule and delivery of the therapeutic agent to the interior of the
tumor cell. To generate single chain Fv (scFv) antibodies capable of triggering receptor-mediated endocytosis, we previously developed a
method to directly select phage antibodies for internalization by recovering infectious phage from the cytoplasm of the target cell. Using this
methodology, we reported the selection of a panel of scFv that were internalized into breast cancer cells from a nonimmune phage library. For
this work, an immunotherapeutic was generated from one of these scFv (F5), which bound to ErbB2 (HER2/neu). The F5 scFv was
reengineered with a C-terminal cysteine, expressed at high levels in Escherichia coli, and coupled to sterically stabilized liposomes. F5 anti-
ErbB2 immunoliposomes were immunoreactive as determined by surface plasmon resonance (SPR) and were avidly internalized by ErbB2-
expressing tumor cell lines in proportion to the levels of ErbB2 expression. F5-scFv targeted liposomes containing doxorubicin had antitumor
activity and produced significant reduction in tumor size in xenografted mice compared to nontargeted liposomes containing doxorubicin.
This strategy should be applicable to generate immunotherapeutics for other malignancies by selecting phage antibodies for internalization
into other tumor types and using the scFv to target liposomes or other nanoparticles.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Many targeted therapeutic approaches to cancer require
endocytosis of the targeting molecule and delivery of the
therapeutic agent to the interior of the tumor cell. Such drug
targeting strategies rely on the use of ligands capable of
binding to tumor cell surface receptors in a manner that
triggers receptor endocytosis. Antibodies have been suc-
cessfully used as surrogate receptor ligands for intracellular
targeting of toxins [1], liposomes [2], drugs and DNA [3].
Currently, antibodies that trigger internalization are identi-
fied by screening antibodies derived by either hybridoma or
phage antibody technology [4]. This usually involves gen-
erating and examining antibodies recognizing specific tar-
gets. While such approaches may take the biology of the
target receptor into account, they do not necessarily select
for the requisite biology of the antibody, triggering receptor
endocytosis. This limits the availability of useful targeting
antibodies, since many surface receptors do not undergo
endocytosis and for those that do, the efficiency with which
an antibody mediates internalization can vary significantly
depending on the epitope recognized [5,6].
We recently developed a strategy to directly select
internalizing antibodies from phage libraries by recovering
infectious phage from within a target cell line [7]. The
technique was applied to select a panel of antibodies from a
naı¨ve phage library [8] that were specifically endocytosed
into the breast tumor cell line SK-BR-3 [9]. Upon further
characterization, two of the antibodies (F5 and C1) were
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identified as binding ErbB2, a growth factor receptor over-
expressed in 20–30% of human breast carcinomas as well
as other adenocarcinomas. In this work, we demonstrate
how such scFv antibodies can be used to construct a targeted
drug with potent antitumor activity. Specifically, we engi-
neered the anti-ErbB2 F5 scFv for conjugation to amphi-
pathic PEG for construction of immunoliposomes by
membrane capture into preformed stealth liposomes, yield-
ing anti-ErbB2 immunoliposomes. Such F5 immunolipo-
somes are efficiently endocytosed by ErbB2-expressing
tumor cell lines and have potent antitumor activity in
xenografted mice, which significantly exceeds that of untar-
geted doxorubicin-containing liposomes. This strategy of
selecting internalizing antibodies from phage libraries and
construction of immunoliposomes provides a generic, rapid
and facile route for making targeted therapeutics for many
types of tumors.
2. Methods
2.1. Construction of expression vector pELK
A fragment containing the pelB leader and cloning sites
from vector pUC119mycHis [10] was amplified using
standard PCR conditions. Primers were designed to append
a 5VXbaI site and a 3VSalI site for cloning into pET9a
(Promega). The alkaline phosphatase promoter (PhoA) from
Escherichia coli was then cloned as an EcoRI/XbaI frag-
ment yielding the pELK expression vector.
2.2. F5 scFv expression
A C-terminal cysteine followed by a stop codon was
added to the F5 scFv by PCR using primers G4C-NotI (5V-
GCT CTA GAT CAG CAG CCT CCA CCG CCA CCT
AGG ACG GTC AGC TTG GTC CC-3V) and LMB3 [11].
The PCR product was cloned into the NcoI/NotI sites of
vector pELK. ScFv was expressed from E. coli strain
RV308 (ATCC) by fermentation, essentially as described
in Ref. [12]. Soluble protein obtained as a periplasmic
extract [12] was purified on recombinant protein A agarose
(Pharmacia).
2.3. Conjugation of F5 scFv to maleimide-PEG-DSPE
F5 scFv was reduced on a thiol-reducing column (Reduc-
eImm, Pierce) according to the manufacturers’ instructions,
except guanidine was omitted from the running buffer and
reduction time was 30 min at room temperature. Alterna-
tively, F5 scFv was incubated in 144 mM NaCl, 20 mM
MES, pH 6.0 in the presence of 10 mM cysteamine hydro-
chloride and 5 mM EDTA at 32 jC for 1 h, and isolated by
passage through a desalting column (PD-10, Pharmacia).
The number of free thiol groups per molecule was deter-
mined with Ellman’s reagent as described by the manufac-
turer (Pierce). The reduced scFv was incubated overnight at
4 jC with maleimido-PEG2000-distearoyl-phosphatidyletha-
nolamine (Avanti Polar Lipids) in 144 mM NaCl aqueous
buffer at pH 6.5–7.5 at a protein/linker molar ratio of 1:4.
The amounts of conjugated and free protein were deter-
mined by SDS-PAGE with Coomassie staining and band
densitometry. For in vitro studies, and to afford quantitation
of liposome-conjugated scFv, 1 mg of scFv (prior to con-
jugation) was labeled with 0.3 ACi of 125I using IodoBeads
(Pierce) as described by the manufacturer.
2.4. 125I-labelling and internalization study
Purified F5 scFv was labeled with 125I as above and
incubated (10 Ag/ml) with live SK-BR-3 cells in 12-well
plates (150,000 cells/well) for 15, 30, 60, or 90 min at 37
jC. After washing four times with Hanks’ balanced salt
solution (HBSS; Gibco) without phenol red, cell surface
bound antibody was removed by two 10-min washes with 1
ml glycine buffer (glycine 50 mM, pH 2.8, adjusted to the
osmolarity of 290 mmol/kg with NaCl). Cells were lysed in
0.1% Triton-100 and internalized and cell surface associated
radioactivity measured in a Packard gamma counter. Ki-
netics of endocytosis was fitted using Berkeley Madonnak
differential equations solver (available at http://www.
berkeleymadonna.com).
2.5. Liposome preparation
For in vitro assays, liposomes were prepared from 1-
palmitoyl-2-oleoyl-phosphatidylcholine (POPC), choles-
terol, and methoxy-poly(ethylene glycol (M.W. 2000)-dis-
tearoylphosphatidylethanolamine (PEG2000-DSPE) (3:2:0.3
molar ratio) (all from Avanti Polar Lipids) by lipid film
hydration in a solution containing membrane-impervious
fluorescent marker, followed by extrusion through track-
etched polycarbonate membranes with pore size 100 nm [2].
For internalization studies, the solution contained pH-sensi-
tive marker trisodium 8-hydroxypyrene-1,3,5-trisulfonate
(HPTS); 35 mM, pH 7.0 [2,13]. For fluorescence micro-
scopy, the marker was 20 mM BODIPY disulfonate (both
probes from Molecular Probes). Both dye solutions were
adjusted to the osmolarity of 290 mmol/kg with NaCl. For
in vivo therapeutic efficacy studies, Doxil (Alza Corp.)
obtained commercially was used for immunoliposome for-
mation. Doxil contains unilamellar liposomes (70–90 nm)
composed of hydrogenated soy phosphatidylcholine, cho-
lesterol, and PEG2000–DSPE (3:1:0.3 by mass) and doxor-
ubicin (0.15 mg/Amol of phospholipid) encapsulated into
the liposomes by an ammonium sulfate gradient method
[14,15].
Immunoliposomes were formed by overnight incubation
of the PEG-DSPE-conjugated F5 scFv with preformed
liposomes at 37 jC, followed by the removal of nonincor-
porated F5 conjugate, nonconjugated scFv, and any extra-
liposomal low-molecular-weight molecules by gel chroma-
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tography using a Sepharose 4B column (Pharmacia). The
liposomes were excluded from the gel and recovered in the
void volume fraction. Separation of micelles from lip-
osomes was confirmed as follows: 0.5 ml of F5-PEG-DSPE
(1.6 mg/ml protein) or 0.5 ml of doxorubicin liposome
(Doxil) diluted to 0.2 mg/ml of doxorubicin with HEPES-
buffered saline (HBS, 5 mM HEPES, 144 mm NaCl, pH
7.4) were applied onto a column (diameter 1.5 cm, bed
volume 13 ml) with Sepharose 4B (Pharmacia Amersham)
and eluted with HBS. Fractions (0.5 ml) were collected and
spectrophotometrically analyzed for F5 protein (absorbance
at 280 nm) or doxorubicin (absorbance at 485 nm). The
amounts of F5 or doxorubicin per fractions were expressed
as percent of total applied. Total recovery of both F5-PEG-
DSPE and doxorubicin liposomes in the eluted fractions was
>97%. To afford quantification of liposome-linked F5, the
protein was labeled with 125I, purified by gel chromatog-
raphy, reduced, and finally conjugated to maleimido-PEG-
DSPE. The resulting 125I-F5-PEG-DSPE conjugate was
mixed with the unlabeled conjugate at a ratio of 1:9 and
subsequently incubated with POPC/cholesterol/PEG-DSPE
liposomes at various protein-to-liposome ratios (2–100
scFv/liposome). Liposome concentration was determined
by phosphate analysis adapted from Morrison [16]. Doxor-
ubicin in the liposome and immunoliposome preparations
was quantified by spectrophotometry at 485 nm after
solubilization of liposomes in 70% aqueous isopropanol–
0.1 N HCl.
2.6. Immunoliposome analysis by surface plasmon
resonance (SPR)
Binding activity of immunoliposomes was determined by
SPR in a BIAcore1000 instrument (BIAcore Inc.). Approx-
imately 3000 RU of ErbB2 ECD were coupled to a CM5
sensor chip (BIAcore) as described [10] and binding rates
were measured under continuous flow of 15 AL/min.
Immunoliposomes were injected at a concentration of 50
AM phospholipid. To determine the kinetics of immunoli-
posome binding to ErbB2, serial dilutions of recombinant
ECD were incubated with 50 AM immunoliposomes for 1 h
prior to binding analysis. Binding activity was determined
from a linear standard curve of binding slope versus con-
centration.
2.7. Flow cytometry analysis
Human cancer cells SK-BR-3, SK-OV-3, BT474, MCF7,
MDA-MB-453, MDA-MB-231, MDA-MB-468 (ATCC)
were grown to 80–90% confluence in the media type recom-
mended by ATCC and supplemented with 10% fetal calf
serum (FCS). The ErbB2 transfected cell line MCF7/HER2
was grown as previously described [17]. F5 scFv (20 Ag/ml),
containing a version of the FLAG epitope tag with improved
affinity [18,19], was used to detect the levels of ErbB2
expression by flow cytometry as previously described [18].
2.8. Spectrofluorometric measurement of immunoliposome
uptake by cells
Tumor cells were grown in 96-well plates to subconflu-
ency. To determine cellular uptake or kinetics of internal-
ization, immunoliposomes containing HPTS were incubated
at 200 AM total phospholipid in a 37 jC incubator in
complete cell culture media for the indicated times. After
washing four times with HBSS without phenol red, fluo-
rescence was read at 512 nm following excitation at 414
and 454 nm, in a Gemini microfluorometer (Molecular
Devices). Total cellular uptake of liposomes was calculated
from the fluorescence at isosbestic point (414 nm), and the
amount of endocytosed liposomes was determined from the
fluorescence at 454 and 414 nm excitations as described
[13,20].
2.9. Fluorescence microscopy
SK-BR-3 cells were grown in 12-well plates to subcon-
fluency. Immunoliposomes containing approximately 60
scFv per liposome and loaded with BODIPY disulfonate
(final concentration 100 AM phospholipid) were incubated
with SK-BR-3 cells for 2 h at 37 jC in complete media
along with 5 Ag/ml of tetramethylrhodamine-labeled trans-
ferrin (Molecular Probes). The cells were then washed six
times in HBSS and live cells were examined through a
Nikon Eclipse 300 inverted fluorescence microscope.
2.10. In vivo antitumor efficacy studies
Antitumor efficacy studies were preformed as previously
described [25]. Briefly, tumor xenografts were raised sub-
cutaneously (s.c.) in 5-week-old female homozygous nude
mice (NCR nu/nu) using a subline of BT474 human breast
adenocarcinoma cells (ATCC HTB-20), which contain about
106 ErbB2 receptors/cell [21]. The subline (BT474M1) with
increased tumorigenicity was derived from BT-474 xeno-
grafts selected for maximum growth rate [25]. The animals
were inoculated s.c. at the base of the right scapula with
2 107 BT474M1 cells in 0.1 ml of the growth medium.
Two days prior to inoculation, a 60-day sustained release
17h-estradiol pellet (0.72 mg; Innovative Research of Amer-
ica) was implanted s.c. near the base of the tail [22]. When
tumor xenografts had become fully established (300–400
mm3), the mice were randomly assigned to treatment groups
of 15 animals per group. F5-immunoliposomal doxorubicin
or liposomal doxorubicin (Doxil) were administered intra-
venously at 5 mg doxorubicin/kg once weekly for three
consecutive weeks (total doxorubicin dose of 15 mg/kg).
Control group received i.v. injections of the excipient (HBS)
at the same schedule as liposomes and immunoliposomes.
Tumors were measured twice weekly using a caliper, and
tumor volumes were calculated by multiplying length
width thickness of the tumor and expressed as the mean
for each group (mm3F S.E.). Statistical significance of the
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differences between tumor sizes among the groups was
determined by Student’s t-test.
3. Results
3.1. Isolation of tumor-specific scFv antibodies by selection
for internalization
A naı¨ve scFv phage antibody library containing 7 109
members [8] was selected for endocytosis into SK-BR-3
tumor cells [7,9]. In this selection strategy, the phage anti-
body library was allowed to bind to the cell surface of live
SK-BR-3 cells at 4 jC, unbound phage was removed by
washing and cells were subsequently incubated at 37 jC for
15 min to allow internalization of the phage. Phage remain-
ing on the cell surface were removed with acid washes and
internalized phage recovered by infection of the cell lysate
into E. coli. This strategy allowed the isolation of rapidly
internalizing phage antibodies [7,9]. After three rounds of
selection, we identified more than 40 distinct scFv that
internalized into SK-BR-3 cells. One of these antibodies,
F5, was shown to recognize the extracellular domain (ECD)
of ErbB2 with a KD of 160 nM and was efficiently
endocytosed into SK-BR-3 cells as phage and as purified
monomeric F5 scFv [9].
3.2. Kinetics of internalization into tumor cells
The kinetics of internalization into live SK-BR-3 tumor
cells overexpressing ErbB2 was investigated using F5 scFv
labeled with 125I. Following incubation from 0 to 90 min,
cell surface-bound antibody fragments were stripped with
low pH glycine buffer and the fraction of internalized and
cell surface bound antibody determined by measuring radio-
activity. A plot of time versus the amount of internalized
antibody fragment allowed determination of the rate of
internalization (results not shown). The internalization rate
was 0.0056 min 1 for the F5 scFv.
3.3. Reengineering and expression of the scFv for
construction of immunoliposomes
To provide a single thiol group as a convenient and
unique site for conjugation to a drug delivery carrier, the F5
scFv was reengineered by PCR to contain the C-terminal
sequence Gly-Gly-Gly-Gly-Cys followed by a stop codon,
and was cloned into the expression vector pELK. This
vector consists of the pET9 backbone with an alkaline
phosphatase promoter cloned in place of the pET9 promoter.
The scFv containing the C-terminal cysteine expressed at
high levels (>20 mg/l) by fermentation in E. coli. The F5
scFv sequence belongs to the VH3-gene family of which
approximately 50% bind protein A [23]. This was the case
for the F5 scFv, allowing for a one-step affinity purification
on immobilized protein A, following which the recombinant
protein was more than 90% pure as judged by SDS-PAGE
(Fig. 1).
3.4. Conjugation of the F5 scFv to a lipid linker and
formulation into liposomes
Immunoliposomes are usually made by direct conjuga-
tion of the antibody to liposomes formulated with activated
lipid anchors for coupling of antibody to the liposome
surface [24]. However, construction of immunoliposomes
by membrane capture of amphipathic antibody–PEG con-
jugates into preformed liposomes offers a new and efficient
method of immunoliposome construction [25,26].
Fig. 1. SDS-PAGE analysis of F5 scFv purification, reduction, and coupling
to maleimide-PEG-DSPE and analyses of F5-PEG-DSPE insertion into
liposomes. (A) Lane 1: F5 scFv purified using protein A chromatography;
lane 2: protein A-purified F5 scFv after reduction on a ReduceImm column;
lane 3: F5 scFv after conjugation to maleimido-PEG-DSPE; lane 4: F5 scFv
after incorporation into liposomes and purification of immunoliposomes by
gel filtration on Sepharose 4B. (B) F5-PEG-DSPE or doxorubicin liposome
(Doxil) were applied onto a Sepharose 4B column and eluted with HBS.
Fractions were collected and spectrophotometrically analyzed for F5
protein (absorbance at 280 nm) or doxorubicin (absorbance at 485 nm). The
amounts of F5 or doxorubicin per fractions were expressed as percent of
total applied. The arrow marks the column total volume (V0).
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Initial preparations of the F5 scFv contained approxi-
mately 0.1 free thiol groups per molecule and existed as a
mixture of monomers and covalent dimers (Fig. 1, lane 1).
Therefore, this protein was reduced to make the thiol group
of the C-terminal cysteine available for conjugation. Fol-
lowing elution from a thiol-reducing column, or by treat-
ment with cysteamine hydrochloride at pH 6.0, a majority of
the dimer was reduced to the monomeric form (Fig. 1, lane
2), resulting in 0.7–1.2 free thiol groups per molecule for
conjugation to an amphipathic linker, N-(N-(N-maleimido)-
poly(ethylene glycol)2000-a-oxycarbonyl-distearoyl phos-
phatidylethanolamine (PEG2000-DSPE). Coupling of the
reduced protein to the PEG2000-DSPE linker increases the
apparent molecular size of the scFv by approximately 3
kDa, so the reaction could be monitored by SDS-PAGE
(Fig. 1, lane 3). The coupling reaction routinely yields 75–
95% of scFv coupled to PEG2000-DSPE, preserving >80%
of immunoreactivity as determined by BIAcore analysis
(results not shown). Preservation of immunoreactivity as
well as the absence of conjugates comprising more than one
linker (single conjugate band in Fig. 1, lane 3) suggests that
despite the presence of additional scFv cysteines involved in
intramolecular V-domain disulfide bonds, the reduction
conditions were specific to the thiol group engineered onto
the C-terminus of the scFv, thus providing the single attach-
ment site to PEG2000-DSPE.
Upon incubation of antibody–PEG-DSPE conjugates
with preformed liposomes, the hydrophobic DSPE domain
spontaneously incorporates itself into the liposome lipid
bilayer, thus ‘‘tethering’’ the antibody ligand to the liposome
surface [25,26]. Incubation of scFv-PEG-DSPE conjugate
with commercial liposomal doxorubicin (Doxil, Alza) at
30–40 scFv/liposome overnight at 37 jC resulted in 75–
90% incorporation of the conjugate into drug-loaded lip-
osomes. Similar incorporation efficiency was achieved in
the range of 2–100 scFv/liposome using HPTS-loaded uni-
lamellar liposomes of POPC, cholesterol, and PEG2000-
DSPE (3:2:0.3 molar ratio), which have lipid bilayers in
the fluid state as opposed to gel state of Doxil liposome
bilayer [14,15]. Leakage of encapsulated HPTS or doxor-
ubicin during this process was quite low, typically less than
3% (results not shown). SDS-PAGE analysis confirmed
efficient incorporation of F5 conjugate into the liposomes
and complete removal of all extraliposomal proteins by
subsequent gel-chromatography on Sepharose 4B (Fig. 1,
lane 4). The efficient separation of F5-PEG-DSPE micelles
and the liposomes on the Sepharose 4B column was de-
termined by spectrophotometrical analyses of the fractions
and showed that the conjugate and the liposomes are re-
solved (Fig. 1B).
3.5. Effect of the scFv density on antigen binding and
intracellular uptake of F5-immunoliposomes
The binding of immunoliposomes containing 2–100
scFv/liposome to ErbB2 was investigated by SPR under
mass transport limiting conditions [27], well below saturat-
ing concentrations of immunoliposomes. The rate of binding
to ErbB2 ECD was directly proportional to the number of
scFv/liposome (r= 0.99), as shown in Fig. 2A.
The equilibrium binding constant (KD) for the scFv
antibody binding to the ErbB2 ECD was also determined
by SPR. Following incubation of F5-immunoliposomes
with varying amounts of soluble extracellular domain of
ErbB2, the binding concentration was determined by SPR,
Fig. 2. Effect of scFv density on the binding of immunoliposomes to ErbB2
and on the uptake by SK-BR-3 cells. (A) Effect of scFv density on
immunoliposome binding to the ErbB2 extracellular domain as determined
by SPR. Immunoliposomes were formed by incorporation of varying
amounts of scFv-PEG-DSPE conjugate into preformed 100 nm POPC/
cholesterol/PEG-DSPE liposomes and analyzed in a BIAcore 1000 instru-
ment. Measurements were made at an immunoliposome concentration of 50
AM of liposome phospholipid. (B) Effect of scFv density on the total uptake
of anti-ErbB2 immunoliposomes by SK-BR-3 cells. Immunoliposomes were
incubated with the cells at 100-fold excess over total cellular ErbB2 receptors
for 12 h and concentration of 50 AM of liposome phospholipid. Error bars
represent the standard deviation of triplicate experiments.
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also under mass transport limited conditions. Because the
slope of the mass transport limited SPR signal of the
liposome binding is directly proportional to the concentra-
tion, the KD can be determined by fitting the data as
described [27,28]. The KD for the monovalent binding of
F5 scFv conjugated to the liposome (KD = 111nM) is in
close agreement with the 160 nM KD value of soluble,
unconjugated F5 scFv for ErbB2, also determined by SPR,
indicating that conjugation to the liposome does not sig-
nificantly affect the monovalent interaction with the antigen.
Varying the density of scFv fragments on the liposome
surface from 0 to 30 scFv/liposome produced a dramatic
increase in cellular uptake, which reached a maximum
uptake value at 30 scFv/liposome (or approximately 1 scFv
per 1300 phosholipids in the outer leaflet of the liposome).
Increasing the number of scFv from 30 to 100 per liposome
did not increase uptake further (Fig. 2B). This result is
comparable to our previously reported result (approximately
40 Fab’/liposome) for the trastuzumab-Fab’-conjugated lip-
osomes [2] as well as with the findings of Maruyama et al.
[29] showing that 30 IgG molecules per liposome are
optimal for tumor cell uptake.
3.6. Specificity of F5-immunoliposome uptake into
ErbB2-expressing tumor cells
To investigate the dependence and specificity of F5-
immunoliposome uptake on ErbB2 cellular expression, total
cellular uptake was determined for a number of tumor cell
lines with varying ErbB2 expression levels (Fig. 3). For
comparison, the relative antigen expression on the same cell
lines was determined by flow cytometry using F5 scFv
containing the FLAG tag sequence, detected with anti-
FLAG FITC conjugated antibody. Overall, F5-immunolipo-
some uptake correlated with increasing ErbB2 expression
(r = 0.80); uptake in cell lines having low ErbB2 expression
(MDA-MB-468, MDA-MB-231, and MCF7) was two to
three orders of magnitude below that of ErbB2-overexpress-
ing cell lines (MCF7/HER2, BT474, SK-OV-3, and SK-BR-
3). The specificity of the F5 immunoliposome uptake is
further exemplified by its uptake into the ErbB2-transfected
and overexpressing MCF7/HER2 cells. The transfected
MCF7/HER2 subline takes up two orders of magnitude
more of the F5 immunoliposomes than the parental MCF7
cells that express 45-fold lower levels of ErbB2 receptor
[17]. Among the ErbB2 overexpressing cell lines, however,
total F5 immunoliposome uptake correlated poorly
(r = 0.56) with the magnitude of ErbB2 overexpression.
For example, SK-OV-3 cells accumulated less than half
the total amount of F5 immunoliposomes compared to SK-
BR-3 cells, despite comparable levels of ErbB2 overexpres-
sion (Fig. 3). This may relate to the greater abundance of an
alternatively spliced ErbB2 transcript in SK-OV-3 cells [30].
Excess extracellular domain encoded by this alternative
transcript, which confers resistance to trastuzumab (Hercep-
tin) when transfected into sensitive cell lines, is sequestered
in the perinuclear Golgi and may interfere with endocytosis
of surface membrane, full-length, ErbB2 [30].
3.7. Cell internalization and endosomal accumulation of
F5-immunoliposomes
For fluorescence microscopy studies of the cells with F5-
immunoliposomes, where the marker sensitivity to pH was
undesirable, BODIPY-disulfonate (BODIPY-DS) was sub-
stituted for HPTS. BODIPY-DS loaded F5-immunolipo-
somes and tetramethylrhodamine-labeled transferrin were
co-incubated with SK-BR-3 cells at 37 jC. F5-immunoli-
posomes quickly entered the cells (Fig. 4A). Unlike trastu-
zumab-Fab’-containing immunoliposomes [2], F5-immuno-
liposomes did not co-localize with transferrin but rather
accumulated into a perinuclear compartment consistent with
the late endosomes. Incubation of F5-immunoliposomes
with MCF7 cells did not result in any detectable uptake.
Thus, F5 immunoliposomes efficiently entered cells in
ErbB2 receptor-specific manner and appeared to accumulate
Fig. 3. Effect of cell surface ErbB2 expression as determined by flow
cytometry on the total cellular uptake of anti-ErbB2 immunoliposomes. (A)
Total uptake of F5 immunoliposomes after 12 h of incubation. (B) ErbB2
expression level as determined by flow cytometry with the F5 scFv detected
by anti-FLAG FITC. Error bars represent the standard deviation of triplicate
experiments.
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in a late endosomal compartment. The kinetics of internal-
ization of F5 immunoliposomes containing approximately
30 scFv per liposome determined using the pH-sensitive dye
HPTS [2,13,20] (0.017 min  1; Fig 5B) was three-fold
higher than the internalization rate determined for the
unconjugated scFv (0.0056 min  1). A similar correlation
has been reported for liposomes conjugated with transferrin
[31].
3.8. In vivo efficacy of doxorubicin delivered by
F5-immunoliposomes
Using a xenograft model of a human ErbB2 overexpress-
ing breast cancer (BT474) [32], we compared the antitumor
Fig. 5. Efficacy of anti-ErbB2 immunoliposomes in a human ErbB2-
overexpressing breast cancer model. (A) Anti-ErbB2 immunoliposome-
Doxil containing the F5 scFv (triangles) were administered i.v. on days 18,
25, and 32 (arrows) at a total doxorubicin dose of 15 mg/kg as indicated in
the text. The control treatment group was treated with Doxil at the same
doxorubicin dose (circles). (B) Anti-ErbB2 immunoliposome-Doxil con-
taining the F5 scFv (triangles) administered on days 21, 28, and 35 (arrows,
same dose as above) are compared to control (PBS) treatment (open
circles). Data represent mean tumor volumes; mm3F S.E.
Fig. 4. Binding and endocytosis of F5 immunoliposomes by ErbB2-
overexpressing tumor cells. (A) Immunofluorescence analysis of F5-
liposomes loaded with BODIPY (yellow/green) and transferrin-tetrame-
thylrhodamine (red) after 2 h of co-internalization into SK-BR-3 cells. (B)
Kinetics of anti-ErbB2 immunoliposomes uptake by SK-BR-3 cells at 200
AM of liposome phospholipid. Depicted are the internalized fraction (closed
circles) and surface bound fraction (closed triangles).
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efficacy of doxorubicin-loaded F5-immunoliposomes
derived from a commercial preparation of sterically stabi-
lized liposomal doxorubicin (Doxil) with that of parental
(nontargeted) Doxil. In animals with large (350–400 mm3)
subcutaneous tumors, three weekly i.v. injections of F5-
immunoliposomal doxorubicin (5 mg/kg) produced substan-
tial tumor regressions (Fig. 5A). After the second and third
treatments, tumor regressions in the F5 targeted group were
significantly superior to nontargeted Doxil (P= 0.001 by
two-tailed nonpaired Student’s t-test) and far superior to the
control PBS treatment (Fig. 5B).
4. Discussion
Receptor-mediated endocytosis is an essential first step
for many antibody targeted therapeutic approaches, includ-
ing immunotoxins, immunoliposomes, antibody–drug con-
jugates and antibody targeted gene delivery (reviewed in
Ref. [33]). Since the efficiency of antibody-mediated endo-
cytosis varies considerably depending on the antigen and
epitope recognized [34,35], it typically has been necessary
to screen for antibodies capable of mediating cell internal-
ization by individual labeling of antibodies or antibody
fragments. We recently developed a method to directly
select internalizing antibodies from phage libraries [7] by
panning on a target cell line. Selection is not directed at a
specific cell surface receptor, but rather the panel of recep-
tors capable of internalization. Using this approach, a panel
of antibodies were selected from a naı¨ve phage library that
internalized into the breast tumor cell line SK-BR-3 [9].
Here we demonstrate that such antibodies can be used to
generate a targeted therapeutic with significant antitumor
activity in vivo.
For construction of the antibody-targeted therapeutic
agent, we selected the F5 scFv that binds the ErbB2 growth
factor receptor tyrosine kinase. ErbB2 (HER2/neu) is a
protooncogene, which is overexpressed in 20–30% of
human breast carcinomas as well as in gastric, lung, colon,
ovarian and pancreatic adenocarcinomas (for review, see
Ref. [36]). ErbB2 represents a therapeutic target for anti-
body-mediated drug delivery as it undergoes endocytosis in
response to antibodies binding certain extracellular epitopes
[2,6,35]. In addition, the clinical relevance of ErbB2 as a
cancer target has been validated by the recent FDA approval
of the anti-ErbB2 antibody trastuzumab for breast cancer
therapy.
We chose to use the F5 scFv to target doxorubicin-con-
taining liposomes. Liposomes are attractive vehicles for
drug encapsulation since they can carry large amounts of
drug and provide protection from degradation in the circu-
lation. A number of recent advances in liposome technology
have led to the optimization of liposomal drug carriers for
effective anticancer treatment in vivo (for review, see Ref.
[37]). For example, steric stabilization by coating liposomes
with polymers such as polyethylene glycol (PEG) greatly
increases their circulation time due to increased resistance to
clearance by the mononuclear phagocyte system (MPS),
thus facilitating selective extravasation in solid tumors
[38,39]. The sterically stabilized liposomes do not directly
enter the tumor cells but accumulate within the tumor in-
terstitium where the drug then passively diffuses into the
tumor cells [37,40]. Therapeutic efficacy can be improved
by delivering the liposomes directly into the tumor cells.
Indeed, anti-ErbB2 immunoliposomes containing doxorubi-
cin and targeted by the Fab’ fragment of trastuzumab are
endocytosed by ErbB2-expressing cells and have shown
greater therapeutic efficacy against ErbB2-overexpressing
xenografts than liposomal doxorubicin in the absence of
targeting, although targeting does not increase the overall
tumor uptake of liposomal drug [2,41]. The degree of be-
nefit from liposomal targeting appears to depend to some
extent on the degree of cellular internalization of the immu-
noliposome upon receptor binding. Likewise, lack of immu-
noliposome internalization following receptor binding is
associated with poor cytotoxicity and lack of therapeutic
advantage [42–45].
To investigate the potential for tumor targeting by scFv
selected for internalization, the F5 scFv was engineered for
coupling to liposomes. A C-terminal cysteine was engineered
into the F5 scFv molecule and a high level expression vector
constructed using the phoA promoter and kanamycin resist-
ance. The resulting expression system is tightly regulated,
easily scalable to larger fermentation vessels, and uses a
resistance marker compatible with clinical good manufactur-
ing practice (cGMP). Since the F5 scFv contains a VH gene
derived from the human VH3 family, it binds protein A. This
allows the elimination of epitope tags frequently used for
purification, such as hexahistidine, which could pose a
regulatory hurdle. These vector and scFv gene modifications
were incorporated to facilitate pharmaceutical production of
F5 immunoliposomes and ensure the possibility of future
clinical translation.
F5 scFv coupling to prefabricated liposomes first
required its conjugation via the engineered C-terminal
cysteine’s free thiol to the maleimide group formed at the
free end of a PEG-DSPE linker. Use of a PEG linker
prevents neighboring liposomal PEG molecules from inter-
fering with antibody binding of the cell surface receptor [2];
thus, the affinity of the liposome-conjugated F5 was essen-
tially equal to that of the free scFv. Such thiol-reactive
PEG–lipid linkers previously have been applied to con-
struct liposomes with conjugated Fab’ fragments [2] and
whole antibodies [29,46,47]. The presence of hydrophilic
PEG domain prevents precipitation of the conjugate that
stays in aqueous solution presumably in a micellar form.
However, the presence of a hydrophobic lipid tail results in
the capture of scFv-linker conjugate into preformed lip-
osomes by simple mixing. This afforded a single-step
conversion of commercial doxorubicin-loaded liposomes
into anti-ErbB2 immunoliposomes with high yield (75–
90%).
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In vitro, ErbB2-overexpressing cells showed specific
uptake of F5-immunoliposomes into ErbB2 overexpressing
cells in proportion to their endocytotic capacity. Fluores-
cence of liposome-entrapped dye pointed to endosomal
accumulation by the internalized F5 immunoliposomes.
However, F5 immunoliposomes did not co-localize with
transferrin. Rather, the F5 immunoliposomes appeared to
localize into a perinuclear compartment consistent with the
late endosomes.
The F5 scFv is of entirely human origin. This eliminates
the need for timely and costly cloning and humanization of
antibodies undertaken to evade an human antimouse
(HAMA) immune response. Incorporation of humanized
antibodies into immunoliposomes may also lead to an
increased HAMA response compared to free antibody due
to enhanced immunogenicity from uptake of antibody
coated liposomes into reticulendothelial cells. This could
result in increased opsonization and uptake into macro-
phages and consequently a shorter circulation time [48].
Immunogenicity should be less for completely human anti-
body fragments. In addition, the F5 scFv does not have
growth inhibitory properties of the FDA approved anti-
ErbB2 antibody, trastuzumab [49], which may be linked
to the high incidence of cardiotoxicity in patients treated
with trastuzumab, especially when administered along with
doxorubicin [50].
In summary, we believe this approach provides a generic
route for rapid development of antibody targeted drugs with
potent in vivo antitumor activity. Human antibodies are
selected from phage libraries for internalization into a target
tumor cell line and the biology and specificity of the
selected antibodies is confirmed by secondary screens.
The scFv genes are subcloned into the high level expression
system described here and the purified scFv conjugated to
linker and immunoliposomes formed by membrane cap-
ture. If efficacy is verified in the appropriate animal model,
then expression and purification can be scaled up for
current good manufacturing practice (cGMP) manufacture.
For example, based on preclinical data partially described
in this publication, the F5 scFv expression plasmid has
been transferred to the National Cancer Institute Mono-
clonal Antibody and Recombinant Protein facility for ex-
pression and purification scale up and possible cGMP
manufacturing. Using the membrane capture system, a single
batch of cGMP antibody could be used to target liposomes
carrying other anticancer pharmaceuticals or the scFv anti-
body may be coupled to other nanoparticle delivery systems,
toxins or drugs using the conjugation chemistry described
here.
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